New Delhi : Drug major Sun Pharmaceutical Industries said its subsidiary has received approval for Tobramycin from the European Medicines Agency.
The approval for the product was received by company’s wholly owned subsidiary firm from the European Medicines Agency, Sun Pharmaceutical Industries said in a filing to BSE.
The company and its subsidiaries continue to file multiple products across multiple countries on an on-going basis, Sun Pharma said while replying to a clarification on a news report sought by the exchange.
“However this is not a material development for the company,” it added.
Shares of Sun Pharmaceutical Industries today closed at Rs 649.30 per scrip on BSE, up 4.31 per cent from its previous close.
Latest posts by supriya kashyap (see all)
- Natco’s partner Alvogen gets nod for influenza drug in US - November 6, 2017
- USFDA moves to more efficient global pharmaceutical manufacturing inspections - November 6, 2017
- Sanofi refines expectations on drop in sales at diabetes arm - November 6, 2017